A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01685255
Recruitment Status : Terminated (Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.)
First Posted : September 14, 2012
Last Update Posted : March 26, 2018
Information provided by (Responsible Party):
Incyte Corporation

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 23, 2014
  Actual Study Completion Date : October 23, 2014
  Certification/Extension First Submitted : November 4, 2015